Lawsone
Based on 2 publication(s) in Google Scholar
Lawsone is an orally active naphthoquinone dye that can be isolated from the leaves of Lawsonia inermis. Lawsone can induce apoptosis. Lawsone has antibacterial, antitumor and antioxidant activities. Lawsone can be used in anti-tumor drug research.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.54%
- No. CAS: 83-72-7
- Fòrmula: C10H6O3
- Peso molecular:174.16
-
Almacenamiento:
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Natural Product Library
HY-L021
-
Anti-Cancer Compound Library
HY-L025
-
Antioxidant Compound Library
HY-L037
-
Antifungal Compound Library
HY-L048
-
Antibacterial Compound Library
HY-L049
-
Medicine Food Homology Compound Library
HY-L055
-
Orally Active Compound Library
HY-L061
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Cancer Natural Product Library
HY-L107
-
Plant-Sourced Natural Product Library
HY-L115
-
Human Metabolite Library
HY-L123
-
Cell Death Library
HY-L162
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
PBCRBS Traditional Chinese Medicine Compound Library
HY-L193
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
RO5 Drug-like Natural Product Library
HY-L200
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Cosmetic Ingredient Compound Library
HY-L221
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Mongolian Medicine Compound Library
HY-L238
-
Quinones Library
HY-L243
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Lawsone
More
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Cell Proliferation/Viability Assay
Actividad biológica
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
58 μM
Compound: 17
|
Growth inhibition of human A549 cells by MTT assay
Growth inhibition of human A549 cells by MTT assay
|
[PMID: 24374273] |
| HeLa | IC50 |
>100 μM
Compound: 1c
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 24913712] |
| HeLa | IC50 |
71.26 μM
Compound: 1
|
Cytotoxicity against human HeLa cells
Cytotoxicity against human HeLa cells
|
[PMID: 33766765] |
| Hepatocyte | CC50 |
>500 μM
Compound: Lawsone
|
Cytotoxicity activity against Swiss Webster mouse primary hepatocytes assessed as reduction in cell viability after 72 hrs by cell-titer-glo assay
Cytotoxicity activity against Swiss Webster mouse primary hepatocytes assessed as reduction in cell viability after 72 hrs by cell-titer-glo assay
|
[PMID: 29289882] |
| HFF-1 | IC50 |
>50 μM
Compound: 7
|
Cytotoxicity against HFF-1 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
Cytotoxicity against HFF-1 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
|
[PMID: 34438124] |
| Hs 683 | IC50 |
31 μM
Compound: 17
|
Growth inhibition of human Hs683 cells by MTT assay
Growth inhibition of human Hs683 cells by MTT assay
|
[PMID: 24374273] |
| KB | IC50 |
105.48 μM
Compound: 1
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 33766765] |
| LoVo | IC50 |
>100 μM
Compound: 17
|
Growth inhibition of human LoVo cells by MTT assay
Growth inhibition of human LoVo cells by MTT assay
|
[PMID: 24374273] |
| MCF7 | IC50 |
>50 μM
Compound: 1
|
Cytotoxicity against ER-positive human MCF7 cells assessed as redution in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against ER-positive human MCF7 cells assessed as redution in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31810778] |
| MDA-MB-231 | IC50 |
>50 μM
Compound: 1
|
Cytotoxicity against triple-negative human MDA-MB-231 cells assessed as redution in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against triple-negative human MDA-MB-231 cells assessed as redution in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31810778] |
| PC-3 | IC50 |
>100 μM
Compound: 17
|
Growth inhibition of human PC3 cells by MTT assay
Growth inhibition of human PC3 cells by MTT assay
|
[PMID: 24374273] |
| SAS | IC50 |
>100 μM
Compound: 1c
|
Cytotoxicity against human SAS cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human SAS cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 24913712] |
| SK-BR-3 | IC50 |
>50 μM
Compound: 1
|
Cytotoxicity against HER2-positive human SKBR3 cells assessed as redution in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against HER2-positive human SKBR3 cells assessed as redution in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31810778] |
| SK-MEL-28 | IC50 |
>100 μM
Compound: 17
|
Growth inhibition of human SK-MEL-28 cells by MTT assay
Growth inhibition of human SK-MEL-28 cells by MTT assay
|
[PMID: 24374273] |
| U-373MG ATCC | IC50 |
>100 μM
Compound: 17
|
Growth inhibition of human U373 cells by MTT assay
Growth inhibition of human U373 cells by MTT assay
|
[PMID: 24374273] |
| Vero | CC50 |
213.74 μM
Compound: Lawsone
|
Cytotoxicity activity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by cell-titer-glo assay
Cytotoxicity activity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by cell-titer-glo assay
|
[PMID: 29289882] |
Lawsone (125, 250, 500 μM, 18 h) inhibits the growth of Escherichia coli in a dose-dependent manner[3].
Lawsone (0.5, 1, 1.5, 2 mg/mL, 48 h) inhibits cell proliferation in human DLD-1 cells by reducing NF-κB activity, resulting in inhibition of the expression levels of cyclin B1 and cdk1[4].
Lawsone (10, 20, 40, 80, 160 mg/mL, 24 h) has an anti-proliferation effect in SKOV-3 ovarian cancer cells and induces apoptosis by inhibiting Bcl-2[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:DLD-1, MRC-5
-
Concentration:0.5, 1, 1.5, 2 mg/mL
-
Incubation Time:24-96 h
-
Result:Demonstrated significant suppression at concentration 2 mg/ml on DLD-1 cells and exhibited no suppression on normal fibroblast MRC-5 cells.
-
Cell Line:DLD-1
-
Concentration:0.5, 1, 1.5, 2 mg/mL
-
Incubation Time:48 h
-
Result:Decreased the level of both proteins cyclin B1 and cdk1. Exhibited a dose-dependent effect on translocation of p65 of cytosol to the nucleus.
Lawsone (200 mg/mL, orally, for 8 weeks) has a significant inhibitory effect on colon cancer in rats[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female rat model (10-11- week-old)[2]
-
Dosage:62.5, 125, 250, 500, 750 μmol/kg/day
-
Administration:p.o.
-
Result:Increased the levels of ALT, AST, GLDH, LDH, HBDH, urea and creatinine at a dose of 500 or 750 μmol/kg/day.
-
Animal Model:Rat model of colon cancer[4]
-
Dosage:200 mg/mL
-
Administration:p.o.
-
Result:Reduced the tumor diameters and decreased multiplicity of these adenomas. Decreased the PCNA staining index
Chemical Information
-
No. CAS 83-72-7
-
Appearance Solid
-
Peso molecular 174.16
-
Fòrmula C10H6O3
-
Color Light yellow to yellow
-
SMILES
O=C1C(O)=CC(C2=C1C=CC=C2)=O
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Int J Biol Macromol
Identification of Vitamin K3 and its analogues as covalent inhibitors of SARS-CoV-2 3CLpro. [Abstract]2021 Jul 31:183:182-192. PMID: 33901557 -
EMBO Mol Med
Modulating CCTG repeat expansion toxicity in DM2 Drosophila model through TDP1 inhibition. [Abstract]2025 Mar 25. PMID: 40133672
Lawsone purchased from MedChemExpress. Usage Cited in: EMBO Mol Med. 2025 Mar 25. [Abstract]
Dose-response analysis of Lawsone and SPI-112. The activity of TDP1 was treated with purified TDP1 enzyme 3.125, 6.25, 12.5, 25, 50, 100, 200 μM. Data are mean ± SD from three biological replicates. IC50 values were calculated using log(inhibitor) compared with normalized response (variable slope), using the program Prism, and are given in graphs.
Lawsone purchased from MedChemExpress. Usage Cited in: EMBO Mol Med. 2025 Mar 25. [Abstract]
Quantification of γ-H2AvD staining intensity in nuclear of body-wall muscles at third instar larvae of Wild-type. Quantification at least five animals of each sample/experiment, five experiments. Data are mean ± SD. Two-tailed, unpaired t test. ***P = 0.0007 CPT versus CPT + Lawsone, ***P = 0.0003 CPT versus CPT + SPI-112.
Lawsone purchased from MedChemExpress. Usage Cited in: EMBO Mol Med. 2025 Mar 25. [Abstract]
Dose-survival analysis of Lawsone and SPI-112. The HEK293 cells were treated with purified TDP1 enzyme 0, 0.001, 0.01, 0.1, 1, 10, 100, 1000 μM for 72 h. Data are mean ± SD from three biological replicates. IC50 values were calculated using log(inhibitor) compared with normalized survival rate (variable slope), using the program Prism, and are given in graphs.
Solvente y solubilidad
DMSO : 100 mg/mL (574.20 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (14.36 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (14.36 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (281 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Tripathi RD, et al. A fungitoxic principle from the leaves of lawsonia inermis lam. Experientia. 1978 Jan 15;34(1):51-2. [Content Brief]
[2]. Munday R, et al. Haemolytic activity and nephrotoxicity of 2-hydroxy-1,4-naphthoquinone in rats. J Appl Toxicol. 1991 Apr;11(2):85-90. [Content Brief]
[3]. Sauriasari R, et al. Cytotoxicity of lawsone and cytoprotective activity of antioxidants in catalase mutant Escherichia coli. Toxicology. 2007 Jun 3;235(1-2):103-11. [Content Brief]
[4]. Wang SB, et al. Lawsone suppresses azoxymethane mediated colon cancer in rats and reduces proliferation of DLD-1 cells via NF-κB pathway. Biomed Pharmacother. 2017 May;89:152-161. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 5.7420 mL | 28.7101 mL | 57.4201 mL | 143.5503 mL |
| 5 mM | 1.1484 mL | 5.7420 mL | 11.4840 mL | 28.7101 mL | |
| 10 mM | 0.5742 mL | 2.8710 mL | 5.7420 mL | 14.3550 mL | |
| 15 mM | 0.3828 mL | 1.9140 mL | 3.8280 mL | 9.5700 mL | |
| 20 mM | 0.2871 mL | 1.4355 mL | 2.8710 mL | 7.1775 mL | |
| 25 mM | 0.2297 mL | 1.1484 mL | 2.2968 mL | 5.7420 mL | |
| 30 mM | 0.1914 mL | 0.9570 mL | 1.9140 mL | 4.7850 mL | |
| 40 mM | 0.1436 mL | 0.7178 mL | 1.4355 mL | 3.5888 mL | |
| 50 mM | 0.1148 mL | 0.5742 mL | 1.1484 mL | 2.8710 mL | |
| 60 mM | 0.0957 mL | 0.4785 mL | 0.9570 mL | 2.3925 mL | |
| 80 mM | 0.0718 mL | 0.3589 mL | 0.7178 mL | 1.7944 mL | |
| 100 mM | 0.0574 mL | 0.2871 mL | 0.5742 mL | 1.4355 mL |
Lawsone Related Classifications
HY-N2493 Related Classifications
Powered by Bioz